Remove Contract Manufacturing Remove Development Remove Insulin
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin.

Insulin 328
article thumbnail

FDA rejects Provention’s type 1 diabetes drug teplizumab

pharmaphorum

Three months ago, the FDA said it was unconvinced by a bridging study designed to show equivalence between Provention’s product intended for commercial sale, made by contract manufacturer AGC Biologics, and the drug that teplizumab’s original developer Eli Lilly used in clinical trials.

Drugs 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Outsourcing Peptide Synthesis: Preferred Choice of Drug Developers

Roots Analysis

The peptide therapeutics market has undergone substantial evolution since the inception of insulin. It is noteworthy that peptide is a complex class of drugs that possess many manufacturing challenges, including complex process and big-budget development and manufacturing.

article thumbnail

FDA sets August decision date for Provention’s type 1 diabetes drug

pharmaphorum

Teplizumab is thought to work by binding to CD3, preventing the activation of T cells that attack and kill insulin-producing pancreatic beta cells in the autoimmune disease. In the latter, teplizumab wasn’t able to show an impact on insulin use or HbA1c, an indirect measure of glucose control over time.

Drugs 52
article thumbnail

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

pharmaphorum

” T1D occurs when the immune system attacks and destroys the insulin-producing pancreatic beta cells that make insulin, and occurs in three stages. In stage 1 there are antibodies against the beta calls, but blood glucose levels remain normal and there are no symptoms.

Drugs 52
article thumbnail

Sartorius Stedim Biotech to acquire Novasep’s chromatography process equipment division

The Pharma Data

Novasep’s chromatography unit comprises resin-based batch and intensified chromatography systems, and primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides and insulin.

article thumbnail

Decline of novel drug approvals means less business for cutting-edge CMOs

Pharmaceutical Technology

This is mixed news for contract manufacturing organisations (CMOs), as large CMOs such as Thermo Fisher Scientific (Waltham, MA, US) and Catalent Inc (Somerset, NJ, US) are typically involved in the manufacture of the most innovative products. The drug increases insulin synthesis and release.

Drugs 130